Mitsubishi Tanabe Pharma Corporation

Kenji Morokuma

Kunio Saruta

Hiroaki Shitama

Norimitsu Hayashi

Osamu Sakurai

Ritsuo Imashiro

Hiroaki Sawamoto

Joji Tsurumoto

Hidekazu Tsujishima

Takashi Goi

Atsushi Sato

Yasuo Yamamoto

Maiko Hamada

Seigo Ishibuchi

Takashi Adachi

Tetsuji Matsudaira

Naoto Fujie

Akiko Tarao

Maki Seki

Takashi Honjo

Masahiko Miyashiro

Yukio Aoyama

Atsushi Kawata

Shingo Ogata

Nobuatsu Matoba

The present invention provides: a methyl 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound.

Optically active pyrrolidine compound and method for producing same

Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

Imide derivatives and use thereof as medicine

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; Rrepresents an optionally substituted alkyl group or the like; Rrepresents a halogen atom or the like; and Ris an alkyl group substituted with an optionally substituted aryl group or the like, and Ris a hydrogen atom or the like; or Rand Rare terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof. 

Pyrrolidine compound and application as melanocortin receptor agonist

This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. 

Continuous arycyclic compound

Growing community of inventors

Osaka, Japan

Kenji Morokuma